PD173212 is primarily used in research settings as a selective inhibitor of the fibroblast growth factor receptor (FGFR). Its application is significant in studying the role of FGFR signaling pathways in various biological processes, including cell proliferation, differentiation, and survival. Researchers utilize PD173212 to investigate its potential therapeutic effects in diseases where FGFR signaling is dysregulated, such as certain types of cancers. By inhibiting FGFR, it helps in understanding the molecular mechanisms underlying tumor growth and progression, providing insights for developing targeted cancer therapies. Additionally, it is employed in preclinical studies to evaluate its efficacy and safety as a potential drug candidate.